Adopted opinions and previous consultations on applications for authorisation

This page provides further information on the applications for authorisation or review reports, which have undergone consultation. The applications for authorisation are in the opinion development phase until the final opinions of the Committees for Risk Assessment and Socio-economic Analysis have been adopted and sent to the European Commission. Its decision-making process can be followed through the comitology register, where further information is published about the REACH Committee's past and upcoming meetings.

On 1 February 2020, the United Kingdom (UK) withdrew from the EU. The transition period provided by the withdrawal agreement ended on 31 December 2020. As of 1 January 2021, an application for an authorisation submitted by a person established in the UK (except Northern Ireland) is no longer valid in the EU, unless that application has been transferred to a legal entity established in the EU or Northern Ireland before the end of the transition period. Therefore, authorisation applications and decisions in so far as these concern persons established in the UK (except Northern Ireland) are no longer considered valid.

ID	Application type	Name	EC Number	CAS Number	Applicant(s)	Use name	Status
0139-01	Initial	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	Ortho-Clinical Diagnostics - [Application void as of 01/01/2021]	Formulation of 4-(1,1,3,3-Tetramethylbutyl) phenol, ethoxylated (as Triton X-100) for use in the manufacture of in vitro diagnostic VITROS® products used for infectious disease screening, endocrinology, and oncology testing.	Application void as of 01 January 2021
0163-01	Initial	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	Wallac Oy	Formulation of 4-(1,1,3,3-Tetramethylbutyl) phenol, ethoxylated (as Triton X-100) into enhancement solutions and DELFIA standard and maintenance solutions used in In Vitro Diagnostic assays and RUO products as well as maintenance of instruments as a critical ingredient for detection process while measuring europium (or other lanthanide) content of the assay solution	Commission decided
0188-01	Initial	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	Wallac Oy	Formulation of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (as Triton X-100) for use in the assay buffer for the GSP® Neonatal GALT kit used for the semi-quantitative determination of galactose-1-phosphate uridyl transferase (GALT) activity	Commission decided
0185-02	Initial	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	IDEXX Montpellier SAS	Formulation of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated in the manufacture of sample diluents and standard solutions used in in vitro diagnostic veterinary ELISA Plate tests used for the detection of infectious diseases in livestock and poultry	Commission decided
0090-01	Initial	Formaldehyde, oligomeric reaction products with aniline	500-036-1	25214-70-4	Polynt Composites France	Formulation of an epoxy resin hardener containing technical MDA	Commission decided
0234-01	Initial	Chromium trioxide	215-607-8	1333-82-0	Maschinenfabrik Kaspar Walter GmbH & Co KG	Formulation of chromium trioxide-based electrolyte for electroplating process.	Opinions adopted
0002-01	Initial	Bis(2-ethylhexyl) phthalate (DEHP)	204-211-0	117-81-7	ARKEMA FRANCE	Formulation of DEHP in compounds, dry-blends and Plastisol formulations	Withdrawn
0003-01	Initial	Bis(2-ethylhexyl) phthalate (DEHP)	204-211-0	117-81-7	Grupa Azoty Zakłady Azotowe Kędzierzyn S.A.	Formulation of DEHP in compounds, dry-blends and Plastisol formulations	Withdrawn
0004-01	Initial	Bis(2-ethylhexyl) phthalate (DEHP)	204-211-0	117-81-7	DEZA a.s.	Formulation of DEHP in compounds, dry-blends and Plastisol formulations	Withdrawn
0011-01	Initial	Diarsenic trioxide	215-481-4	1327-53-3	Linxens France SA	Formulation of diarsenic trioxide into a mixture	Commission decided

Showing 51 - 60 of 486 results.

Export in:

EU Privacy Disclaimer